Difficulties in hematopoietic progenitor cell collection from a patient with TEMPI syndrome and severe iatrogenic iron deficiency.
BACKGROUND
Collection of hematopoietic progenitor cells by apheresis (HPC-A) requires separation of cells by density. Previous studies highlighted the challenges of HPC-A collection from patients with abnormal red blood cells (RBCs). TEMPI syndrome is a recently described condition defined by teleangiectasias, elevated erythropoietin and erythrocytosis, monoclonal gammopathy, perinephric fluid collections, and intrapulmonary shunting. Patients with TEMPI syndrome have responded to therapies used to treat plasma cell dyscrasias and may benefit from autologous HPC transplantation. We report HPC-A collection from a patient with TEMPI syndrome that was complicated by severe iron deficiency.


METHODS
The patient received granulocyte-colony-stimulating factor (G-CSF) and plerixafor for HPC mobilization and underwent 3 days of HPC-A collection.


RESULTS
The patient presented for collection with a microcytic erythrocytosis. Over 3 days, approximately 50 L of whole blood was processed, and 2 × 10(8) CD34+ cells were collected (2.8 × 10(6) CD34+ cells/kg). The mean collection efficiency (CE), percentage of mononuclear cells, hematocrit (Hct), and RBC count were 18%, 90%, 14%, and 9 × 10(11) , respectively. Altering collection variables to avoid RBC contamination reduced CE. Ficoll preparations of the products after freeze-thaw showed RBC contamination and hemolysis. Postthaw viability exceeded 95%. The products were not RBC reduced or washed. There were no adverse reactions during or after infusion.


CONCLUSIONS
HPC-A collection from a patient with TEMPI syndrome was complicated by microcytic erythrocytosis, leading to RBC contamination and hemolysis in the product. Adequate HPCs were collected and the patient tolerated infusion without RBC depletion or washing. Our report highlights difficulties of HPC-A collection from iron-deficient patients.
Department of Pathology, Brigham and Women's Hospital; Massachusetts General Hospital, Boston, Massachusetts.
Roger
R
Belizaire
Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
David B
DB
Sykes
Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Yi-Bin A
YB
Chen
Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Thomas R
TR
Spitzer
Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Robert S
RS
Makar
D001596:Benzylamines; D000080027:Cyclams; D016238:Cytapheresis; D004913:Erythrocytes, Abnormal; D004921:Erythropoietin / Q000097:blood*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells; D006571:Heterocyclic Compounds / Q000008:administration & dosage; D006801:Humans; D007674:Kidney Diseases / Q000097:blood*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010265:Paraproteinemias / Q000097:blood*; D011086:Polycythemia / Q000097:blood*; D013577:Syndrome
D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor